Emory-CDC HIV/AIDS Clinical Trials Unit

AIDS   Clinical Trials Group (ACTG): ACTG A5353

Title   of Study: A study to evaluate Dolutegravir plus lamivudine dual therapy   for the treatment of naïve HIV 1 infected participants.

Brief   Description:

A5353   is a study for people who are infected with HIV and have never taken HIV   medications. Participants will receive Dolutegravir plus Lamivudine for 52   weeks.

Inclusion/   Exclusion Criteria:

Abbreviated   List of Inclusion/Exclusion Criteria


  •   HIV 1 infected men and women at least 18 years of age
  •   Have not taken HIV medications (cept for PrEP)
  •   No evidence of resistance to the type of anti-HIV drugs being   used in the study
  •   Have blood HIV level (viral load) of at least 1000 copies/ml but   less than 500,000 copies/ml
  •   No active hepatitis B infection
  •   No active/current hepatitis C treatment


DTG 50   mg once daily plus 3tc 300 mg once daily

Study   Duration:

52   weeks

For   more information contact:

Ericka   R. Patrick, RN, MSN